Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Manuscript information
  • Supplemental material
  • Footnotes
  • References
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research LetterGeneticsPublic HealthPulmonology Open Access | 10.1172/JCI211620

A Mucin-5B variant associated with idiopathic pulmonary fibrosis may prolong survival in the general population

Mitchell J. Riley,1 Jacob E. Simmering,1 and Michael J. Welsh1,2

1Department of Internal Medicine,

2Department of Molecular Physiology and Biophysics, Pappajohn Biomedical Institute, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.

Address for correspondence. Michael J. Welsh, 169 Newton Rd., 6332 PBDB, University of Iowa, Iowa City, Iowa, 52242, USA. Phone: 319.335.7619; Email: michael-welsh@uiowa.edu.

Find articles by Riley, M. in: PubMed | Google Scholar

1Department of Internal Medicine,

2Department of Molecular Physiology and Biophysics, Pappajohn Biomedical Institute, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.

Address for correspondence. Michael J. Welsh, 169 Newton Rd., 6332 PBDB, University of Iowa, Iowa City, Iowa, 52242, USA. Phone: 319.335.7619; Email: michael-welsh@uiowa.edu.

Find articles by Simmering, J. in: PubMed | Google Scholar |

1Department of Internal Medicine,

2Department of Molecular Physiology and Biophysics, Pappajohn Biomedical Institute, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.

Address for correspondence. Michael J. Welsh, 169 Newton Rd., 6332 PBDB, University of Iowa, Iowa City, Iowa, 52242, USA. Phone: 319.335.7619; Email: michael-welsh@uiowa.edu.

Find articles by Welsh, M. in: PubMed | Google Scholar |

Published November 16, 2026 - More info

Published in Volume 136, Issue 22 on November 16, 2026
J Clin Invest. 2026;136(22):e211620. https://doi.org/10.1172/JCI211620.
© 2026 Riley et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published November 16, 2026 - Version history
View PDF

To the Editor: Idiopathic pulmonary fibrosis (IPF) is a rare fibrotic, interstitial lung disease that progressively destroys the lung. Genome-wide association studies identified a common single-nucleotide polymorphism in the MUC5B gene promoter (rs35705950, T allele) in ≥ 50% of people with IPF (1). The MUC5B G allele is the common allele; the T allele occurs in approximately 20% of the general population and is associated with an approximately 5-fold increased risk of developing IPF. Throughout, the T allele refers to both GT and TT genotypes. The high prevalence and low penetrance of a variant conferring an elevated risk for a lethal disease raised the question of whether the T allele might provide an evolutionary benefit. Two observations brought further suspicion about this possibility: IPF patients carrying the T allele are reported to have a later onset of disease and longer survival after diagnosis (2). Therefore, we tested the hypothesis that the T allele is associated with a survival advantage.

Previous studies focused on people who have established IPF. To evaluate the general population for the risk associated with the T allele, we analyzed data from 232,401 participants in the All of Us Research Program’s database (Supplemental Table 1; supplemental material available online with this article; https://doi.org/10.1172/JCI211620DS1). The T allele was associated with a four-fold increased hazard ratio (HR) of developing IPF (Figure 1A and Supplemental Table 2), consistent with previous reports (1).

Assessment of IPF diagnosis and all-cause mortality risk.Figure 1

Assessment of IPF diagnosis and all-cause mortality risk. Throughout, red indicates participants with a T allele, blue with GG alleles, whiskers indicate 95% confidence intervals, shaded regions indicate 95% confidence bands, and A–C used a Wald statistical test. (A) T allele HR for IPF diagnosis unadjusted and adjusted for the indicated covariates (4.0, [95% CI, 2.7–5.7]). ***, P < 0.001 for the all adjustments estimate. (B) Fine-Gray competing risks cumulative incidence curve, HR = 3.9, P < 0.001. (C) T allele HR for all-cause mortality, unadjusted and adjusted for the indicated covariates (0.91, [0.83–0.999]); * P = 0.048 for the all adjustments estimate). (D) Kaplan-Meier survival analysis. P = 0.043 by log-rank test. Inset shows increased survival associated with the T allele at age 79.

Because smoking and male sex have been associated with an increased risk of IPF, we asked if they confound assessment of T allele effects. Smoking was associated with an increased IPF HR, and male sex had a time-varying HR for IPF, suggesting that the relative IPF hazard between males and females varied by age (Supplemental Table 2). However, adjustment for smoking, sex, and predicted ancestry did not change the hazard associated with the T allele (Figure 1A).

We found that participants with the T allele were diagnosed at a younger age than participants with GG alleles (Figure 1B). This contrasts with a previous study of a group of patients with IPF, which reported that patients with T allele were older at diagnosis (2). By studying people enrolled before an IPF diagnosis, our analysis avoids biases associated with competing risks (Supplemental Material).

To test if the T allele is associated with a survival advantage in the general population, we assessed all-cause mortality. The T allele was associated with decreased all-cause mortality (Figure 1C and Supplemental Table 3). The associated lower hazard of death in people with the T allele persisted after testing for potential confounding relationships with smoking, sex, and predicted ancestry. Both smoking and male sex had time-varying HR (Supplemental Table 3). Kaplan-Meier analysis revealed that participants with a T allele had ≥ 1% increase in survival between ages 55–78 and ≥ 2% between ages 79–95 (Figure 1D). A UK Biobank study serendipitously also found the T allele associated with improved male survival from all-cause mortality (3). These results reveal a potential association between the MUC5B T allele and survival. Validation of these results will require studies of additional databases.

Might the T allele confer an evolutionary benefit even though its association with increased survival appears late in life? First, theory and evidence suggest that prolonged postreproductive lifespans can provide fitness advantages in humans and selected other species (4). Second, the average enrollment age in the All of Us database was 53 years, preventing assessment in children and young adults. Thus, we speculate that the relatively high frequency of the T allele reflects survival advantages in late and/or early life.

What might account for a survival benefit? For most of history, infectious diseases have been the leading cause of mortality. In respiratory airways, MUC5B contributes to mucociliary transport, a key defense against inhaled pathogens. The T allele increases MUC5B expression (1), raising the possibility that elevated MUC5B secretion enhances airway host defense. Accordingly, UK Biobank and Million Veterans Program studies reported an association between the T allele and fewer COVID-19–related hospitalizations (5, 6). We found that the T allele was not associated with a reduced risk of COVID-19 but was associated with a reduced hospitalization risk (Supplemental Figure 1). We found no difference in risk for the combined group of all lung infections or accompanied hospitalizations. We speculate that the T allele may confer protection against some severe respiratory infections. Additional studies may reveal further insights into these interesting results.

Our study has limitations. (a) Numbers of death records are small and lack cause-of-death data. (b) Relatively few participants had IPF, and diagnoses were determined from participant electronic health records. (c) The study population was limited to participants of European or Admixed-American ancestry (Supplemental Material) because All of Us data dissemination policy prohibits reporting case numbers below 20, which restricted our analysis to these ancestries. (d) The database only includes participants ≥ 18 years old; thus, we cannot exclude the possibility that the T allele–associated advantage requires surviving to that age.

The results suggest an evolutionary trade-off, with the IPF risk outweighed by prolonged survival. To illustrate, consider 10,000 people with GG alleles and 10,000 people with a T allele. Compared with GG alleles, the T allele population would be expected to have approximately 10 more people with IPF (the difference in incidence for the T allele versus the GG alleles is ~9.8:10,000, Supplemental Table 1). Conversely, the T allele population would be expected to have approximately 200 more people survive to age 79 (the average USA life expectancy) (2% of 10,000, Figure 1D). Thus, at a population level, the T allele may confer greater evolutionary benefit than risk.

Manuscript information

Conflict of interest. The authors have declared that no conflict of interest exists.

Funding. This study was supported by the following:

  • The Howard Hughes Medical Institute.
Supplemental material

View Supplemental data

View Supporting data values

Footnotes

Copyright: © 2026, Riley et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Reference information: J Clin Invest. 2026;136(22):e211620. https://doi.org/10.1172/JCI211620.

Address for correspondence. Michael J. Welsh, 169 Newton Rd., 6332 PBDB, University of Iowa, Iowa City, Iowa, 52242, USA. Phone: 319.335.7619; Email: michael-welsh@uiowa.edu.

References
  1. Seibold MA, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011;364(16):1503–1512.
    View this article via: CrossRef PubMed Google Scholar
  2. van der Vis JJ, et al. MUC5B rs35705950 minor allele associates with older age and better survival in idiopathic pulmonary fibrosis. Respirology. 2023;28(5):455–464.
    View this article via: CrossRef PubMed Google Scholar
  3. Park J, et al. Rare genetic associations with human lifespan in UK Biobank are enriched for oncogenic genes. Nat Commun. 2025;16(1):2064.
    View this article via: CrossRef PubMed Google Scholar
  4. Croft DP, et al. The evolution of prolonged life after reproduction. Trends Ecol Evol. 2015;30(7):407–416.
    View this article via: CrossRef PubMed Google Scholar
  5. van Moorsel CHM, et al. The MUC5B promoter polymorphism associates with severe COVID-19 in the European population. Front Med (Lausanne). 2021;8:668024.
    View this article via: PubMed Google Scholar
  6. Verma A, et al. A MUC5B gene polymorphism, rs35705950-T, confers protective effects against COVID-19 hospitalization but not severe disease or mortality. Am J Respir Crit Care Med. 2022;206(10):1220–1229.
    View this article via: CrossRef PubMed Google Scholar
Version history
  • Version 1 (November 16, 2026): Electronic publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Manuscript information
  • Supplemental material
  • Footnotes
  • References
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts